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The exponential advances in biological and medical science with the use of 
molecular and genetic testing as well as various “omics” approaches, has led to the 
elucidation of many disease pathways. It has also lead to the identification of 
marked differences in the mechanisms, phenotypes and genotypes of diseases that 
were once thought to have similar characteristics and required similar therapies. An 
example of this approach is in cystic fibrosis where patients with the specific G551D 
mutation respond extremely well to ivafactor (kalydeco)(1). Although this mutation 
is only found in about 5% of all CF patients, their response to treatment is so 
dramatic that it is truly life-changing. On the other hand, the cost of this medication 
is extremely high and it is difficult to imagine that similar costs can be sustained in 
the long term for other, more common diseases. The number of available 
monoclonal antibodies and targeted drugs for severe or life-threatening disease such 
as cancer and rheumatoid arthritis is increasing rapidly, and expected to continue to 
rise in the next decade (2,3). Moreover, we are now faced with the severe end of the 
spectrum of many diseases in which the clinical characteristics and response to 
treatment differ considerably from mild disease.  
    Severe, difficult to treat asthma is such an example: Although asthma is a very 
common disease and although the majority of patients respond well to low dose 
controller medications such as inhaled corticosteroids and long-acting beta2-
agonists, a subset of patients remain uncontrolled despite the use of high-dose 
multiple-drug daily controller therapy. These patients experience substantial 
morbidity due to the disease and to the adverse effects of high-dose corticosteroids 
(4-7) and generate high healthcare costs. The prevalence of such severe, difficult to 
treat asthma is difficult to assess because remediable factors such as nonadherence, 
incorrect inhalation technique and comorbidities play a role in many patients 
referred to specialist care because of uncontrolled asthma despite the use of daily 
controller therapy (4). After addressing these factors in adults, approximately 3-10% 
of patients are estimated to have severe refractory asthma (4-6). In children, such 
studies are rare. In an English multicenter study of asthmatic children with 
uncontrolled asthma despite inhaled corticosteroid use, only 7% of eligible patients 
remained uncontrolled after addressing the basics of asthma management.(8) In a 
recent Dutch study, only 3% of  patients referred for problematic severe asthma 
fulfilled the criteria for true therapy resistant asthma (9).  
Unfortunately, treatment options are limited for severe asthmatics that remain 
uncontrolled despite maximal standard therapy. Omalizumab has been used 
successfully both in children and in adults, and bronchial thermoplasty is an option in 
adults with therapy-resistant severe asthma (10-12). A humanized monoclonal 
antibody to human interleukin 5 mepolizumab was recently approved by the FDA for 
add-on maintenance treatment in patients aged 18 years or older with severe 
eosinophilic asthma (13). Despite these developments there is a lack of 
understanding of severe asthma mechanisms, limiting the possibilities to develop 
novel treatments for severe asthma (14)  
It is becoming increasingly apparent that severe asthma may be due to many 
different mechanisms and that various subsets of severe asthma patients should be 
clustered into specific endotypes, that is, groups with similar clinical and 
pathophysiological characteristics. (4, 15-16) This is particularly true in adults where 
the increased understanding of the multidimensional nature of severe asthma has 
allowed the development of targeted new treatments, such as monoclonal 
antibodies targeting IgE in allergic patients (10), targeting persistent eosinophilic 
inflammation and Th2-high inflammation (17-19), and the search for biomarkers that 
predict a beneficial response to these treatments (20).  
 Although it is assumed that this also applies to severe asthma in children, the 
limited number of studies evaluating children and adolescents with severe asthma 
limits the possibilities for paediatricians to understand and treat this condition even 
further (9,21). 
Identifying specific clusters of patients with severe/difficult to treat disease, 
researching and developing medications for them and monitoring the course of the 
disease and the response to treatment, requires effort, expertise and resources. And 
it requires concerted action. Clinicians, researchers, patients but also the 
pharmaceutical industry and health policy makers should get together, identify the 
pressing needs and the research questions, design a robust research methodology 
and provide the technical and financial resources.  
Over the last 15 years several international collaborative consortia have investigated 
the pathogenetic mechanisms of severe asthma (4,22,23 ). The European Network 
For Understanding Mechanisms Of Severe Asthma (ENFUMOSA) conducted a cross-
sectional study to characterise the clinical and selective inflammatory variables in 
163 adults with severe asthma compared with 158 subjects with well-controlled 
asthma (22). In this study, patients with severe asthma were more often female, had 
worse asthma control and less atopy, and higher sputum neutrophil counts than the 
well-controlled group (22). The National Heart, Lung, and Blood Institute Severe 
Asthma Research Program (SARP) undertook a comprehensive phenotypic 
characterisation of over 583 adults with severe asthma and people with mild and 
moderate asthma as well as 300 children with asthma, recruited mainly from 
academic sites in the US (7,23). In a series of publications the SARP studies have 
provided unique insights into the heterogeneous nature of the inflammatory and 
structural abnormalities associated with severe asthma and identified clusters 
differing in characteristics such as age of onset, BMI, gender and fixed airway 
obstruction(7).  The Longitudinal Assessment of Clinical Course and BIOmarkers in 
Severe Chronic AIRway Disease (BIOAIR) study compared phenotypes defined either 
by biomarkers or by physiological variables in 93 adults with severe asthma and 76 
adults with mild-to-moderate asthma. Phenotypes determined by sputum cell 
counts were less stable than those defined by physiological variables, especially in 
severe asthma (24).  
 
The U-Biopred project 
The most recent international collaborative project in severe asthma is the Unbiased 
Biomarkers for the Prediction of Respiratory Disease Outcome (U-BiOPRED) study. 
This project is designed to identify new phenotypes/endotypes and treatment 
targets using omics technologies (transcriptomic, proteomic, lipidomic and 
metabolomics) (25) and applying a systems biology approach. The project involves 
the integration of data from patient reported outcomes, invasive (in adults) and non-
invasive samples (bronchial biopsies, blood, sputum, urine and exhaled air).  It is 
hoped that this methodology will identify distinct phenotypic handprints of severe 
asthma and result in the unbiased discovery of new treatments for both adults and 
children with severe asthma. The project commenced in 2009 within the framework 
of the EU Innovative Medicines Initiative (IMI) and the consortium involves 
partnerships between 20 academic institutions, 11 pharmaceutical companies and 6 
patient groups. 
 
Two initial articles from this study are published in this issue of the European 
Respiratory Journal, one referring to adult patients and one to children (26-27). 
The first manuscript describes the clinical, physiological and inflammatory features 
of the adult participants recruited to the study and as such is a key publication for 
the interpretation of future reports on the mechanisms of disease identified using 
new technologies. A systematic algorithmic approach developed by the consortium 
was used to evaluate patients presenting with chronic severe asthma symptoms and 
to identify those subjects with severe refractory asthma (28).  
Shaw et al (26) report the results of a cross-sectional study of clinical outcomes and 
inflammatory biomarkers from adults with severe asthma (non-smokers n=311 and 
smokers/ex-smokers n=110), mild/moderate asthma (n=88) and healthy controls 
(n=101) recruited from eleven European countries. A major strength of the study is 
the recruitment of a large cohort of adults with severe refractory asthma.  
The main findings were that patients with severe asthma had worse symptoms, 
more exacerbations despite high dose treatment including oral corticosteroids in 
45% of participants. Severe asthma patients also had higher levels of anxiety and 
depression as well as a higher incidence of co-morbidities of nasal polyps and gastro-
oesophageal reflux compared with patients with mild to moderate asthma. Lung 
function was lower and sputum eosinophils higher in the severe group despite 
receiving more treatment. The clinical features in this U-BIOPRED severe adult 
asthma cohort are in general similar to SARP and ENFUMOSA cohorts. The U-
BIOPRED severe asthma cohort have slightly higher exacerbation rates (2.5 per year), 
lower FEV1 (68% predicted) and high number of patients on oral corticosteroids than 
the SARP and ENFUMOSA cohorts. Eosinophilic airway inflammation was present in a 
similar proportion of patients.   
The inclusion of current smokers with severe asthma (n=42) as well as ex-smokers 
with severe asthma with >5 pack year history (n=68) in the U-BIOPRED cohort is 
important, since both groups were excluded from SARP and ENFURMOS cohorts. 
Adult smokers with asthma, including those with severe diseases, have poor 
symptom control, increased exacerbation rates and high levels of health care 
utilization as well as an attenuated therapeutic response to corticosteroids 
compared to never smokers with asthma (29-31). Current smokers and ex-smokers 
(>10 pack year history) are generally excluded from clinical trials in asthma despite a 
prevalence of 20% to 30% active smoking in the general asthmatic population and 
approximately 10% in severe asthma (29).  
 
It is reassuring to note that the baseline characteristic of the U-BIOPRED cohort are 
similar to patients included in national registries of severe asthma such as the BTS 
Severe Asthma Registry (29,32) and Belgium Severe Asthma Registries (33-34), which 
suggests that findings from U-BIOPRED should be generalizable to ‘real life’ patients 
with severe asthma. 
 
Although both interesting and important, the study by Shaw et al has some 
limitations. First, the classification used to define sub-groups of severe asthma based 
on smoking status may obscure important differences in clinical outcomes and 
inflammatory mechanisms. The adults with severe asthma were classified into two 
groups, a non-smoker subgroup who had a less than five pack-year smoking history 
and second sub-group that combined current smokers (n=42) and ex-smokers with 
greater than five pack-year smoking history (n=68). Although data on the clinical, 
physiological and inflammatory variables in current smokers with asthma compared 
to ex-smokers with asthma is limited, it does suggest that these two groups differ 
(29,35, 36). An alternative classification of never smokers, ex-smokers, subdivided in 
to different pack year histories, and current smokers may provide greater insight 
into possible mechanisms in asthma and in particular those that are related or 
unrelated to current or previous cigarette smoking. Nevertheless, the criteria used to 
classify the severe asthma sub-groups in U-BOIOPRED may be less important when 
the unbiased analyses of the dataset are performed. Secondly, there is relatively low 
number of sample collected for some biological measurements which may influence 
the generalisability of the findings from the new technologies. For example, 
adequate sputum was obtained in only 42-50% of participants and bronchoscopy 
was performed in only 21% of non-smokers with severe asthma, 8% of smokers and 
ex-smokers with severe asthma and 45% of non-smokers with mild/moderate 
asthma. The difference in the number of bronchoscopy samples obtained in each 
group could influence the validly of the results of comparisons between groups in 
inflammatory variables.  
 
The second article is a cross-sectional analysis of baseline data from the paediatric U-
BIOPRED project, in which cohorts of children with severe asthma and severe 
preschool wheezing are compared to those with mild-to-moderate asthma and 
preschool wheeze. The international approach, the combination of school-aged and 
preschool cohorts, and the extensive standardized description of the cohorts are 
major strengths of this paper. Children were recruited in seven paediatric and 
paediatric respiratory units throughout Europe. Comparisons between the cohorts 
with severe disease and those with mild-to-moderate disease showed highly 
significant differences in symptom burden, exacerbation frequency, asthma control 
test results, and (patient’s or parent’s) quality of life. This is not surprising as these 
differences define the distinction between mild-to-moderate and severe disease. 
Much more fascinatingly, there were hardly any differences in demographic, clinical, 
lung function, and inflammatory characteristics between the severe and mild-to-
moderate cohorts. This is clearly different from the situation in adults, where severe 
asthma is distinguishable from mild-to-moderate asthma not only in terms of 
symptoms, but also in physiological and inflammatory characteristics. Why, then, do 
children with severe asthma/wheeze have so much more symptoms and 
exacerbations and a poorer quality of life than children with mild-to-moderate 
disease? Although the “omics” data from the paediatric U-BIOPRED study may shed 
more light on this issue, we should also explore alternative areas of explanation, 
such as psychological issues and family structure and functioning.  
In the paediatric U-BIOPRED study published in this issue of the journal, objective 
evidence of exposure to tobacco smoke at home, was the only putative determinant 
examined which was more common in preschool children with severe wheeze than 
in those with mild-to-moderate wheeze. These differences between children and 
adults in the characteristics in severe asthma call for serious caution in extrapolating 
data from studies in adults to the situation in children. Drugs that work in adults with 
severe asthma may be utterly useless in children with such severe disease, for 
example.  
Another interesting finding in the paediatric U-BIOPRED paper was that 
comorbidities such as food allergy and gastro-oesophageal reflux, though frequently 
reported by parents, were hardly ever confirmed by appropriate testing. This 
highlights the difficulties in charting the prevalence and importance of comorbidities 
in children with asthma (36). The impact of comorbidities of childhood asthma on 
the severity and control of the disease is an area of research which has only recently 
begun to expand. The impact of allergic rhinitis on asthma control has been 
established (37,38) and it is likely that treating allergic rhinitis in children may help to 
control their asthma (20, 37-39). The effects of other comorbidities on asthma 
control and severity in children are poorly studied, however. 
The differences between the findings of the adult and paediatric U-BIOPRED studies 
are fascinating. Whilst the pathophysiological mechanisms of the different 
phenotypes of severe asthma in adults are becoming increasingly clear, the results of 
the paediatric U–BIOPRED study confirm earlier observations that these mechanisms 
in paediatric severe asthma remain largely elusive. This is partly due to ethical 
restraints limiting the possibility of performing invasive diagnostic procedures in 
children, such as bronchoscopy to obtain bronchial biopsies or perform 
bronchoalveolar lavage. The results of the ‘omics’ analyses of the paediatric U-
BIOPRED study are therefore eagerly awaited. 
  
In conclusion, the U-BIOPRED investigators have successfully recruited a large cohort 
of adults and children with severe asthma and collected a wide range of biological 
samples from these patients and controls, which is major achievement. The 
application of unsupervised analyses of the clinical variables and ‘omics’ datasets will 
hopefully help define distinct phenotypes and endotypes of severe asthma and 
identify new treatments. Communication of the results of these analyses is eagerly 
anticipated by the scientific community and by patients with severe asthma who 
currently have limited effective treatment options to alleviate their poorly controlled 
symptoms. 
 
The U-BIOPRED studies are unique in their multidisciplinary collaboration, bringing 
together not only researchers and clinicians, but also pharmaceutical industries and 
patient organizations. Clearly, this is the way forward in our endeavors to 
understand disease mechanisms of severe asthma better, to be able to provide 
effective solutions and medications to help patients with more severe disease. This 
collaborative approach may serve as a model for similar studies in other chronic or 
life-threatening diseases. Understanding disease mechanisms better is only one part 
of the equation leading to better treatment options. Establishing good 
communication among all interested parties, considering all the important questions 
and setting specific goals are other steps, and they must be addressed in 
constructive collaboration between clinicians, researchers, patients, commercial 
parties and health care policy makers. We have to think big but tread carefully, 
meticulously classifying disease characteristics and providing insight, knowledge and 
solutions that are applicable and that can be adopted in everyday clinical practice. 
And we need to discuss the cost will all interested parties so that all solutions can be 
worth pursuing but also financially sustainable long term. 
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